Clinical trials: Anger Management
- Condition Anger Management
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
The purpose of this First-in-Human study is to evaluate the safety , tolerability and pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to placebo.
- Trial name
- NCT03740555
- Testing
- HNC042 single dose, HNC042 multiple ascending doses
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson Disease
First-in-Human Single and Multiple Dose of HL-400
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending…
- Trial name
- NCT06997484
- Testing
- HL-400
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Highlightll Pharmaceutical (USA) LLC
Safety, Tolerability
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B01) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetics
- Trial name
- NCT07285967
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Healthy Volunteers
A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants
ZM-H1505R is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Chronic Hepatitis B. The purpose of this study is to see how safe the study drug is and how well it is tolerated after dosing.
- Trial name
- NCT04220801
- Testing
- ZM-H1505R
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhimeng Biopharma, Inc.
Healthy Volunteers - Male and Female
A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China.
- Trial name
- NCT07313150
- Testing
- QLS7305 Injection
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Safety,, Tolerability,
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of AZD8848 in healthy subjects.
- Conditions
- Safety,, Tolerability,, Healthy Subjects
- Trial name
- NCT01818869
- Testing
- AZD8848
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Single and Multiple Ascending Dose Study for NKTR-118 and Cross-over Study to Investigate the Effect of Food for NKTR-118 in Japanese Healthy Subjects
The purpose of this study is to evaluate the safety and tolerability of NKTR-118 with healthy subjects.
- Trial name
- Japan SMAD (NCT01318655)
- Testing
- NKTR-118
- Where
- Japan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Subjects
A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered AP303 will be assessed in healthy adult subjects.
- Trial name
- NCT05503693
- Testing
- AP303 50 μg, AP303 150 μg, AP303 300 μg
- Where
- Australia
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Alebund Pty Ltd
Weight Management in Adult Patients With Obesity or Overweight
Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult…
- Trial name
- NCT07205432
- Testing
- XTL6001
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shanghai Xitaili Biomedicine Technology co., Ltd.
Post Herpetic Neuralgia, Pain
A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
This study is a 3-part, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamic properties of iN1011-N17 after Oral Administration in Healthy…
- Conditions
- Post Herpetic Neuralgia, Pain, Osteoarthritis, Neuropathic Pain
- Trial name
- NCT06218784
- Testing
- iN1011-N17 HCl Suspension (Part 1), iN1011-N17 HCl Capsule (Part 1), iN1011-N17 HCl Capsule (Part 2)
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- iN Therapeutics Co., Ltd.
Dilated Cardiomyopathy
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of AZD0233 following single and multiple ascending dose (SAD and MAD) administration in healthy participants.
- Trial name
- NCT06381466
- Testing
- AZD0233
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants
TLL018 is developed for treatment of autoimmune and inflammatory diseases including rheumatoid arthritis. The purposes of this study are (1) determining if and at what doses TLL018 is safe and can be tolerated when administered…
- Trial name
- NCT04243083
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- TLL Pharmaceutical, LLC
Healthy
Study of Safety, Tolerability and PK, PD of HPG1860 in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HPG1860 orally administered in…
- Trial name
- NCT04480697
- Testing
- HPG1860
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Hepagene (Shanghai) Co., Ltd.
Healthy, Osteoarthritis
Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation
This is a first in human, randomized, double-blind, placebo-controlled SAD (with food effect) followed by a MAD study of Trichomylin® conducted in healthy adult participants.
- Trial name
- HOPE (NCT04867057)
- Testing
- Trichomylin for SAD, Trichomylin for MAD
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- ZYUS Life Sciences Inc.
Healthy
The Safety, Tolerability, PK, and PD of DWP213388 After SAD and MAD Administration in Healthy Adult Subjects
A Phase 1, First-in-human, Randomized, Double-blind, Placebo controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP213388 after Single and Multiple Ascending Oral Dose Administration in…
- Trial name
- NCT05607589
- Testing
- DWP213388
- Volunteers
- healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants
The study will consist of 2 parts, Study Parts 1 (1a: single ascending dose [SAD] Phase; and 1b: Food Effect Phase) and Part 2 (multiple ascending dose [MAD] Phase).
- Trial name
- NCT07613684
- Testing
- MF-300 SAD, MF-300 Food Effect, MF-300 MAD
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Epirium Bio Inc.
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses of AZD4144 administered orally in healthy participants.
- Trial name
- NCT06122714
- Testing
- AZD4144 Part A, AZD4144 Part B
- Where
- 2 sites in United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabete Mellitus
A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699
This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of YG1699 following single and multiple ascending oral dose administration.
- Trial name
- NCT03953092
- Testing
- YG1699
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Youngene Therapeutics Inc., Ltd.
Healthy Male Subjects, Cardiovascular Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability…
- Trial name
- NCT02632526
- Testing
- AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca